Cardamonin (CD), an active chalconoid, has shown potent anticancer effects in preclinical studies; however, the effect and underlying mechanism of CD for the treatment of triple negative breast cancer (TNBC) is unclear. This study aims to examine the cytotoxic effects of CD and investigate the underlying mechanism in human TNBC cells. The results show that CD exhibits cytotoxicity by inducing apoptosis and cell cycle arrest in TNBC cells via modulation of Bcl-2, Bax, cyt-C, cleaved caspase-3, and PARP. We find that CD significantly increases expression of the epithelial marker E-cadherin, while reciprocally decreasing expression of mesenchymal markers such as snail, slug, and vimentin in BT-549 cells. In parallel with epithelial-mesenchymal transition (EMT) reversal, CD down regulates invasion and migration of BT-549 cells.
Introduction
Triple negative breast cancer (TNBC) accounts for approximately 15-20% of breast cancer cases. TNBC lacks the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression [1, 2] . Because of a high propensity for metastasis and poor prognosis, TNBC is considered the most aggressive of all breast cancers [3] . Current treatment of patients with TNBC is limited to chemotherapy because of the absence of specific targeted therapies [4, 5] . Invasiveness and metastasis are considered as a main reason for TNBC death. In the past few years, an increasing number of studies reported that epithelial-mesenchymal transition (EMT) plays an important role in cancer progression and metastasis [6] [7] [8] .
EMT is a process that is characterized by the loss of epithelial characteristics and acquisition of a mesenchymal phenotype to produce enhanced motility, resistance to apoptosis, and the capacity to invade the surrounding tissues [9] . EMT is a physiological process that is critical for embryonic development and that plays an important role in wound healing and tissue morphogenesis, but which becomes activated during pathological conditions, including fibrosis and cancer [10, 11] . EMT is characterized by decreased adhesion to neighboring epithelial cells and the basement membrane, a specialized network of extracellular matrix (ECM) proteins that underlie epithelial tissues; increased association with interstitial ECM molecules; as well as increased cellular motility [12] . Activation of EMT is associated with altered expression of many genes, including downregulation of epithelial markers, such as Ecadherin and epithelial cytokeratins, and; upregulation of mesenchymal marker genes such as N-cadherin and vimentin [13] [14] [15] . Decrease in the expression of E-cadherin, a cell adhesion receptor found in the basolateral membrane of polarized epithelia, is a hallmark of epithelial tumor cells undergoing EMT. The loss of E-cadherin expression and function has frequently been observed in breast cancer, and its expression is often repressed by several EMT-related transcription factors, such as snail, slug, and ZEB1 [16] . Furthermore, dysregulation of Wnt/b-catenin signaling has been proved to play a significant role in the progression of both the EMT and cancer metastasis. It also plays a critical role in cancer progression in TNBC [17, 18] . b-Catenin is one of the adherent junction components anchored with E-cadherin to regulate cell2cell adhesion and cell migration [19, 20] , and also a key transducer of the Wnt pathway [21] . The stabilization and nuclear accumulation of b-catenin led to stimulation of its target genes-cyclin D1, slug, c-Myc and VEGF, stimulation of EMT, stem cell maintenance, and self-renewal. In addition, accumulation of nuclear b-catenin is a significant marker of enhanced Wnt signaling [22, 23] .
Cardamonin (CD), (2,4-dihydroxy-6-methoxychalcone; [C16H14O4]; molecular mass 270.28) is a naturally occurring chalcone (Fig. 1A) [24] . Several mechanisms of actions of CD were proposed to explain its diverse biological activities, such as anticancer [25, 26] , anti-inflammatory [27, 28] , antioxidant [24] , vasorelaxant [29] , hypoglycemic [30] , anti-infective [31] . Notably, the mechanisms involved in the anti-EMT effects of CD in TNBC are unknown. We hypothesize that CD will exert EMT inhibitory effects through modulating Wnt/b-catenin signaling pathway in TNBC. In this study, we investigated the role of CD in inhibiting EMT and correlated its regulatory effects on the EMT with Wnt/b-catenin signaling pathway in TNBC.
Materials and Methods

Chemicals and Antibodies
CD (97% purity) was purchased from Sigma-Aldrich (St. Louis, MO). Compounds were dissolved in dimethyl sulfoxide (DMSO) and stored as aliquots (20 
Cell Lines
The cell lines used were: MCF-7 (ER 1ve), MDA-MB-231(ER 2ve), and BT-549 (ER 2ve) (Kind gift samples by Dr. Radha, Centre for Cellular and Molecular Biology, Hyderabad, Telangana, India) whereas MCF-10A (human normal breast epithelial cell) cell line was purchased from American Type Culture Collection (ATCC, Manassas, VA). Cells were cultured in DMEM supplemented with 10% fetal bovine serum, penicillinstreptomycin whereas MCF-10A were cultured in base medium for this cell line (MEBM) along with 100 ng/mL cholera toxin. The cells were maintained in a 5% CO 2 /95% air humidified incubator at 37 8C. CD was dissolved in dimethyl sulfoxide (DMSO) with a stock concentration of 100 mM and was freshly diluted to predetermined concentrations with culture medium. The final concentration of DMSO was at 0.05% (v/v). The control cells received the vehicle only. The cells were maintained in a humidified incubator at 37 8C with 5% CO 2 . Cell lines were subcultured by enzymatic digestion with 0.25% trypsin/1 mM EDTA solution when they reached approximately 70-80% confluency.
Cytotoxicity Studies
Cell viability was determined by MTT colorimetric assay [32] . The breast cancer cells (MCF-7, MDA-MB-231, BT-549, and MCF-10A) were seeded at a density of 1 3 10 4 cells per well, in 100 mL of respective medium and were allowed to attach for overnight in a CO 2 incubator. Cells were treated with 0-100 mM CD for 24 and 48 h. After the treatment, 10 mL of MTT (5 mg/mL) in 100 mL medium was added and incubated at 37 8C for 4 h after aspirating the medium with CD. Then the media with MTT was removed and the formed purple formazan crystals were dissolved in 200 mL of dimethyl sulfoxide and read at 570 nm in a multidetection plate reader (Spectramax M4, Molecular devices, USA). Cytotoxicity was expressed as the concentration of CD inhibiting cell growth by 50% (IC50 value).
Colony Formation Assay
BT-549 cells (250 cells/well) were cultured in six well plates overnight and then exposed to designated concentration of CD for 24 h. After rinsing with fresh medium, cells were allowed to grow for 12 days to form colonies. The resulting colonies were fixed and stained with 1% crystal violet (in methanol) for 4 h. The size and number of stained colonies with >50 cells were counted under inverted phase contrast microscope. Colony formation was calculated as a percentage to control cultures [33] .
Assessment of Cell Morphology
Cells (13 10 6 cells/well) were grown in 6-well plates and treated with or without CD at concentrations ranging from 0.5 to 1.5 mM for 24 h. Morphological changes were observed with an inverted phase contrast microscope (Model: Nikon, Japan) and photographs were taken with digital camera (Nikon, Japan) at 2003 magnification. The acridine orange/ethidium MDA-MB-231 cells were exposed to CD at concentrations of (0, 5, 10, and 20 mM) for 24 h and then allowed to grow in drug-free medium in 6-well plates for another 12 days. The resulting colonies were fixed and stained with 1% crystal violet (in methanol) for 4 h. All the values are expressed as Mean 6 SEM of three experiments in which each treatment was performed in triplicate wells. ***P < 0.001, **P < 0.01, and *P < 0.05 versus control.
FIG 1
bromide (AO/EtBr) staining procedure was followed to differentiate the live, apoptotic and necrotic cells [34] 
Cell Cycle Analysis
Cell cycle analysis was carried out using method given by Lee et al., 2012 with slight modifications [37] . To determine the effect of CD on the cell cycle, cells were seeded in six-well plates at a density of 1 3 10 5 cells/mL for 24 h. After incubation, cells were treated with 0.5-1.5 mM for 24 h. After treatment period, cells were collected, washed and fixed overnight in 70% ethanol in PBS at 220 8C. Fixed cells were pelleted and stained with cell cycle analysis reagent for 30 min at 37 8C in dark according to the manufacturer instruction, and about 5000 events were analysed on BD FACSVerse TM cell Analyzer (BD Biosciences, NJ).
Analysis of Mitochondrial Membrane Potential (MMP)
The mitochondrial specific cationic dye JC-1 (Invitrogen, Carlsbad, CA), which undergoes potential-dependent accumulation in the mitochondria was used to detect effect of CD on mitochondrial potential. JC-1 is a monomer when the membrane potential is lower than 120 mV and emits a green light (540 nm) following excitation by blue light (490 nm). At higher membrane potentials, JC-1 monomers convert to J-aggregates that emit a red light (590 nm) following excitation by green light (540 nm) [38] . Briefly, cells were plated at a seeding density of 2 3 10 5 cells/ well in a 12-well plate. After 24 h of treatment with CD (0.5, 1.0, and 1.5 lM), cells were incubated with 5 lM JC-1 for 30 min in dark at room temperature. Fluorescence was monitored with the Multimode Plate Reader at excitation wavelengths of (540 nm) and emission wavelength (590 nm). Changes in the ratio between the measurement at wavelengths of 590 nm (red) and 540 nm (green) fluorescence intensities are indicative of changes in the mitochondrial membrane potential.
Determination of Apoptosis by DNA Fragmentation Analysis
The detection of DNA ladder in agarose gel electrophoresis is used as a biochemical marker for the measurement of apoptosis. It is used to determine the presence of internucleosomal DNA cleavage. Exponentially growing cells (6 3 10 6 ) treated with different concentrations of CD for 24 h were collected, washed in PBS and DNA was isolated according to the method given by Giri et al. with slight modifications [39] . Briefly, 100 lL of lysis buffer (1% NP-40 in 20 mM EDTA, 50 mM Tris-HCl, pH 7.5) was added to the cell pellet for 10 sec. After digestion, the supernatant was collected by centrifugation at 3000 rpm for 10 min. Then supernatant was treated with sodium dodecyl sulfate (final concentration 1%) and RNase A (final concentration 0.1 mg/mL) for 2h at 56 8C, followed by proteinase K (final concentration 0.1 mg/mL) for 2 h at 37 8C. DNA was precipitated by adding half volume of 10 M ammonium acetate and 2.5 volumes of 100% ethanol and the samples were stored for overnight at 220 8C. The DNA was recovered by centrifugation at 13,000 rpm for 15 min at 4 8C. The DNA was resolved by 1.5% agarose electrophoresis at 80-100 V and finally visualized by a UV transilluminator (BIO-RAD, USA).
Wound Healing Assay
A cell-based wound healing assay was performed following well-established methods [40] . Briefly, serum-starved BT-549 cells were grown to 90% confluence and a linear wound was created in the confluent monolayer using a 200 lL micropipette tip. The cells were then washed with PBS to eliminate detached cells and diluted in serum-free DMEM. Then, various concentrations of CD were added for 24 h and 48 h of incubation, and the wound edge closure was monitored with a microscope.
Cell Adhesion Assay
Cell adhesion assay was carried out by a colorimetric method based on staining cells with the dye crystal violet [41] . Briefly, a 24-well culture plate was coated with 10 lg/mL of type I collagen for 24 h at 4 8C, washed twice with PBS, and then plates were blocked with 1% BSA in DMEM for 1 h. BT-549 cells treated with various concentrations of CD in DMEM containing 10% FCS were plated at a density of 1 3 10 5 cells per coated well, followed by 1 h incubation at 37 8C. After washing unattached cells with PBS, adherent cells were fixed in ethanol, stained with 0.1% crystal violet, and then photographed under microscopy at 2003.
Preparation of Total, Cytoplasmic, and Nuclear Protein Extracts
Cells from different experimental groups were homogenized in ice-cold RIPA buffer (Sigma-Aldrich) containing 1% protease inhibitor cocktail (Sigma-Aldrich) and 1% phosphatase inhibitor cocktail (Sigma-Aldrich) to get total protein extracts. Similarly, cytosolic and nuclear extracts were prepared by using NE-PER nuclear and cytoplasmic extraction reagents (Thermo Fisher Scientific, Rockford, IL) containing 1% protease inhibitor cocktail (Sigma-Aldrich) according to the manufacturer's protocol and used for analysis of b-catenin protein expression. The protein contents were measured by using biscinchonic acid (BCA) kit (Pierce Biotechnology, Rockford, IL) against bovine serum albumin (BSA) as standard.
Western Blotting
After treatment with the tested agents as indicated in the figure legends, BT-549 cells were collected and washed twice in 1X PBS, then lysed in RIPA buffer with protease and phosphatase inhibitors on ice for 1 h. Cell lysates were then centrifuged for 15 min at 13,000 rpm at 4 8C. Proteins were separated using SDS-PAGE and subsequently transferred to PVDF (polyvinylidene difluoride) membrane. The blots were blocked with 5% non-fat milk in TBST or 1% BSA (20 mM Tris-HCl, pH 7.4, 137 mM NaCl, and 0.05% Tween-20) at room temperature for 1 h and incubated overnight with the appropriate primary antibody at 4 8C. After washing with TBST, the blots were incubated with peroxidase conjugated secondary antibody for 1 h. To ensure equal protein loading, b-actin was used as an internal control. Bands were monitored using enhanced chemiluminescence reagent (Millipore, USA). The strength of western blotting bands was determined by Image J density measurement program (http://imagej.en.softonic.com).
Luciferase-Based Assay of the Wnt-Dependent Transcriptional Activity
HTB19 (BT-20) triple-negative breast cancer cells (ATCC) were stably transfected with M50 Super 83 TOPFlash plasmid (Addgene, plasmid 12456) at the 20:1 ratio with pcDNA3.1 to provide antibiotic resistance. The best-responding clone was selected and expanded; this line is referred to as HTB19-Tf throughout the text. A luciferase reporter activity measurements were performed essentially as described with several modifications [42] . The HTB19-Tf cells were seeded in 100 mL DMEM medium containing 10% FCS at 10,000 cells/well. After overnight attachment the cells were additionally transfected by the pCMV-RL plasmid for constitutive expression of Renilla luciferase (kindly provided by Konrad Basler) [43] using X-tremeGENE 9 reagent (Roche) according to the manufacturer's protocol. After 24 h cells were stimulated by 0.5mg/ mL mouse Wnt3a purified as described [19] with or without drug compound for 12 h. The medium was subsequently removed, and 15 mL of the lysis buffer (25mM glycylglycine pH 7.8, 1% Triton X-100, 15 mM MgSO 4 , 4 mM EGTA, 1 mM DTT) were pipetted into each well. After incubation for 5 minutes at room temperature the 96-well plate was analyzed in the Victor 3 Multilabel Counter (PerkinElmer) with two-channel dispensing unit primed with the buffer solutions for firefly and Renilla luciferase activity measurements prepared as described in [44] . The final volumes dispensed per well were 50 mL of firefly and 50 mL of Renilla solutions.
Determination of Tumor Inhibition in a Murine Model of Mammary Carcinoma
All animal studies were performed according to the guidelines and approval of the Institutional. Six-to seven-week-old female Balb/c mice were used for all experiments. The mice were housed in groups of four to five animals per cage. To establish tumor grafts, subconfluent breast cancer cells 4T1 were dispersed with 0.1% trypsin/EDTA and washed once with medium containing 5% calf serum to remove the trypsin. The cells were resuspended at a concentration of 8 3 10 5 cells/mL in phosphate-buffered saline. A total of 8 3 10 4 breast cancer cells were injected into the mammary fat pad in mice under the anesthesia and permitted to grow until palpable. At that time, the mice were randomly assigned into control and treatment groups and chemotherapy was initiated. The doses and route of administration for CD was chosen. CD doses (30 mg/kg) was delivered intraperitoneally everyday every 2 days. Control animals received an injection of 0.9% saline solution in volumes equivalent to those used for injection of the drug. Two-dimensional measurements were taken with calipers during the treatment period, and tumor volume was calculated with the use of the following formula: tumor volume (mm 
Statistical Analysis
All results were expressed as mean 6 SEM. The intergroup variation between various groups was measured by one way analysis of variance (ANOVA) using the Graph Pad Prism, version 5.0 and the comparison between groups was conducted by "Bonferroni's Multiple Comparison Test." Results were considered statistically significant when *P < 0.05. 
Results
CD Treatment Induces Cell Death in TNBC but Not in Normal Breast Cells
CD Induces the Execution of Apoptosis Through Activation of the Mitochondrial Pathway
Towards understanding the mitochondrial apoptotic events involved in CD-induced apoptosis, we first analyzed the changes in the levels of proapoptotic proteins Bax antiapoptotic proteins Bcl-2. Western blot analysis showed that treatment of BT-549 and MDA-MB-231 cells with CD increased Bax protein levels in contrast, CD decreased Bcl-2 levels, which led to an increase in the proapoptotic/antiapoptotic Bax/Bcl-2 ratio (Figs. 4A-4D ). Cytosolic extracts were prepared and cytosolic cytochrome c protein levels were measured by immunoblotting analysis. Figure 4E shows that the cytosolic fraction from untreated BT-549 and MDA-MB-231 cells contained very low amounts of cytochrome c, whereas it amounts significantly increased after 24 h of 20 mM CD treatment. Apoptosis was also evident upon examination of common molecular markers of apoptosis, including the caspase-3 activation (Fig. 4F) and cleavage of the caspase substrate PARP into the 89 kDa cleavage product (Fig. 4A) . Both mitochondrial depolarization and the loss of cytochrome c from the mitochondrial intermembrane space have been proposed as the early events during apoptotic cell death. Mitochondria damage is often reported in chemodrug-induced apoptosis [45] . Therefore, we investigated whether CD treatment could cause any mitochondrial damage.
We assessed the integrity of mitochondrial membrane permeability with a fluorescent dye JC-1, which exerts an orange color in healthy mitochondria but a green color when mitochondria are damaged [46] . The results shown in Figs. 5A and 5B revealed that in the majority of CD-treated BT-549 and MDA-MB-231 cells appeared as green color whereas vehicletreated cells were stained red, which was a clear sign of mitochondrial membrane potential transition. We next assessed the effect of CD on the induction of apoptosis in TNBC cells by DNA fragmentation assay. The results showed that CD treatment results in the formation of DNA fragments in TNBC cells, as determined by agarose gel electrophoresis in a dosedependent manner at 24 h (Figs. 5C and 5D ). Taken together, these data demonstrated that CD mainly induced apoptotic cell death in TNBC cells.
CD Exerts Reversion Effect on EMT Markers in BT-549 Cells
We started our investigation by looking at the expression of markers of EMT, which is one of the characteristics that define aggressiveness of breast cancer cells. We chose two breast cancer cell lines that represent mesenchymal phenotype, MDA-MB-231 and BT-549 [47] , -6F ), which was found to be highly significant. E-cadherin expression is repressed by various transcription factors, including snail and slug [48] . Thus, we investigated whether these transcription factors could be involved in the effects of CD on EMT of BT-549 cells. Interestingly, CD downregulated the induction of Ncadherin, slug and snail, in parallel with increased E-cadherin expression (Figs. 6C, 6E , 6H, and 6I). These results suggested an effective switch from MET phenotype of breast cancer cells when exposed to CD. Integrin-mediated adhesion to extracellular proteins, such as fibronectin and collagen, is a key mechanism by which mesenchymal cells acquire increased motility [49, 50] . We hypothesized that CD-induced EMT inhibition might affect cell adhesion to the ECM. To this end, cell-matrix adhesion assay was performed. The data show that BT-549 cells adhesion to the matrix decreased in a dose-dependent manner in response to CD treatment (Figs. 6J and 6K ). Cancer cells undergoing EMT have been considered as an early event that leads to local invasiveness and distant metastasis [51] . Thus, to validate whether EMT conversion by CD is closely linked to the downregulation of Effect of CD on morphological changes. Phase-contrast images (A) BT-549 and (B) MDA-MB-231. Cells (C) BT-549 and (D) MDA-MB-231.treated with CD (0, 5, 10, and 20 mM) for 24 h, and then exposed to 100 lg/mL AO/EB. Chromatin condensation and nuclear fragmentation were considered to indicate apoptotic cells. In experiments, green cells were indicated as live cells; yellow cells were indicated as early apoptotic cells; orange cells were indicated as late apoptotic cells; and red cells were indicated as dead cells. Nuclear morphology determined by DAPI staining, (E) BT-549 and (F) MDA-MB-231 cells treated with CD (0, 5, 10, and 20 mM) for 24 h were stained with 10 lM DAPI dye for 10 min. The cells with bright, fragmented, condensed nuclei were identified as apoptotic cells.
FIG 2
Bt-549 cell invasion, we performed a scratch wound healing assay. This procedure enables the assessment of whether CD affects cell motility. Figures 6L and 6M illustrated that the stimulation of BT-549 cells with Wnt-3a produced a marked wound closure at the leading edge of the wound area at 24 h. Contrastingly, the wounds treated with CD exhibited significant delays in healing after the same treatment period. Collectively, the findings confirm that EMT-reversal mediated by CD is closely associated with the downregulation of the aggressive invasion phenotype of BT-549 cells. 
CD Restores Cytosolic b-Catenin and Suppresses the Nuclear Localization and Function of b-Catenin in BT-549 Cells
We further studied the effect of CD treatment on Wnt signaling pathway to elucidate the mechanism of anticancer action of CD. b-catenin linked to E-cadherin plays a crucial role in the maintenance of adherens junctions and functional epithelia. By contrast, free b-catenin functions as a transcriptional coactivator of the canonical Wnt signaling pathway, which contributes to EMT during tumorigenesis [22] . The dissociation of b-catenin from the cytoplasmic tail of E-cadherin may increase the nonjunctional pool of b-catenin in cytosol, thereby leading to epithelial cell migration [12] . Therefore, to elucidate whether the increase in E-cadherin in response to CD in BT-549 cells is accompanied by the reconstitution of the E-cadherin-b-catenin complex and the suppression of Wnt/bcatenin signaling, the expression, cellular distribution, and function of b-catenin were studied. An inhibition of b-catenin protein levels was observed in the CD-treated BT-549 cells in a dose-dependent manner (Figs. 7A and 7B) . To further verify an effective inhibition of b-catenin by CD, we evaluated the expression of cyclin D1, c-Myc, VEGF, and CDK-4, downstream targets of b-catenin. We found a significant downregulation of cyclin D1, c-Myc, VEGF, and CDK-4 expression in BT-549 cells after CD treatment (Figs. 7A and 7C-7F ). These observations indicate a potent inhibitory action of CD on Wnt signaling Effect of CD on Bcl-2, Bax, cytochrome c, cleaved caspase-3 and PARP in (A) BT-549 and (B) MDA-MB-231 cells. Cells were treated with CD (0, 5, 10, and 20 lM for 24 h) and then harvested. Total cell lysates were prepared and 40 lg proteins was subjected to SDS-PAGE followed by western blot analysis and chemiluminescence detection. Equal loading of protein was confirmed by stripping the western blot and reprobing it for b-actin. Band intensities were quantified using NIH Image J software. The relative protein levels of Bcl-2, Bax, Cyt C, and cleaved caspase-3 were normalized to the b-actin level. Each value was calculated on the basis of the data obtained from three independent experiments. Representative bar diagram showing quantitative results for relative levels of (C) Bcl-2, (D) Bax, (E) Bax/Bcl-2 ratio, (F) Cyt C, and (G) cleaved caspase-3 proteins for CD treated cells. Values are the means 6 SEM (n 5 3).
FIG 4
pathway. We next examined whether CD treatment was associated with changes in the cellular contents and localization of b-catenin protein. Following 24 h treatment with CD, both nuclear and cytosolic cell lysates were collected and used for western blot analysis to determine the amount of b-catenin in each cellular fraction. As shown in Figs. 7G-7I, we found that the amount of b-catenin in the cytoplasmic fraction was not altered by CD treatment at lower concentration, whereas that in the nuclear fraction was markedly decreased by CD. At lower concentration, CD inhibited only translocation of b-catenin to the nucleus whereas at higher concentration CD treatment also diminished cytoplasmic b-catenin levels. To further confirm it, we performed western blotting of b-catenin in the presence Bortezomib (BTZ, proteasome inhibitor). We observed that CD treatment significantly decreased the levels of total b-catenin, as well as phospho-b-catenin (S33/37/T41) (supplementary information). Whereas, the proteasome inhibitor BTZ abolishes the CD-induced degradation of b-catenin. (Fig. 8B) . We further confirm that Wnt-3a induced b-catenin activation was inhibited in CD treated BT-549 cells through the inhibition of nuclear translocation. Indeed, Western blot analysis showed that b-catenin protein abundance was increased with Wnt-3a ligand stimulation in a timedependent manner (Figs. 8C and 8D) . Treatment with Wnt-3a ligand increased b-catenin and decreased E-Cadherin protein expression whereas CD at 20 mM considerably decreased b-catenin and increased E-cadherin protein expression in BT-549 cells when stimulated with Wnt-3a ligand (Figs. 8E-8G ). To determine whether the suppression of b-catenin by CD corresponded to the suppression of b-catenin-mediated transcriptional activities, we investigated its effect on the model of a Wnt dependent cancer-the TNBC cell line HTB19 [42] . This subtype of cancer is known to be especially reliant on the canonical Wnt pathway and disruption of its components is fatal for these cancer cells. By using Top Flash Luciferase reporter assay, we determined b-catenin mediated transcriptional activity in CD treated and control cells. CD showed a concentration-dependent inhibition of Wnt-3a specific Wntdependent transcription, and not on transcription in general (Fig. 8H) . Therefore, the reduction of b-catenin transcriptional activity was in turn to cause the decrease of its transcriptional target gene expression, in terms of the downregulated expression of c-myc, cyclin D1 and cdk4 protein, suggesting that the modulation of Wnt/b-catenin signaling may be a possible course of action through which CD may elicit the EMT reversal of BT-549 cells. . ***P < 0.001, **P < 0.01, and *P < 0.05 versus control. (L) For the wound healing assay, 90% confluent cultures were scraped to form a wound, and then exposed to CD at the indicated concentrations for 24 h. Photos of the wound were captured by microscopy. (M) Relative distance of the wound width was measured and divided by the initial half-width of the wound. Each values are the means 6 SEM (n 5 3). ***P < 0.001 versus the control, ### P < 0.001 and ## P < 0.01 versus Wnt-3a stimulated. 
CD Elevates Degradation of b-Catenin by
Employing the Akt/GSK3b-Dependent Pathway b-catenin stability is controlled by the action of the so-called destruction complex, of which glycogen synthase kinase 3b (GSK-3b) is one of the key components [52] . The phosphorylation of b-catenin by glycogen synthase kinase-3b (GSK3b) targets it for proteasomal degradation. GSK3b activity, in turn, is regulated by its phosphorylation status, with phosphorylation at Ser 9 rendering the protein functionally inactive. One of the upstream regulators of GSK3b is Akt, an upstream kinase directly responsible for the phosphorylation and inhibition of GSK-3b [53] . We wondered if the effects of CD on b-catenin and Values were normalized to control response and the decrease was found to be significant with P-value below 0.01 (**) in case of 25 mM CD.
FIG 8
b-catenin-dependent transcription described above may be due to the action of the drug on Akt-GSK3b. As shown in Figs. 9A, 9C, and 9D markedly decreased the levels of GSK-3b phosphorylation, similarly, the phosphorylated status of Akt was blocked by CD in a dose-dependent manner (Fig. 9B) .To further prove that the effect of CD on b-catenin is indirect but mediated by its action on Akt-GSK3b, we assessed the effect of CD on bcatenin stability in combination with the known GSK3b inhibitor, LiCl. Immunoblot analysis showed that LiCl could protect BT-549 cells from CD-mediated suppression of b-catenin abundance (Figs. 9E and 9F), indicating that GSK3b had a key role in CD-induced b-catenin degradation. These findings provide strong evidence that CD adversely affects the nuclear translocation and transcriptional activity of b-catenin, as well as the main events of Wnt/b-catenin signaling activation, by inhibiting Akt signaling and liberating GSK-3b activity, which then destabilizes b-catenin.
CD-Inhibited Breast Cancer Growth In Vivo
To investigate in vivo anti-tumor effects of CD, murine breast cancer (4T1) model in Balb/c mice was built to evaluate whether CD could suppress tumor growth in vivo. When tumors were palpable, therapy with CD was initiated at 5 and 2.5 mg/kg body weight every day. Control mice received 0.9% saline solution. Representative tumors are shown in Fig. 10A . It was found that treatment with CD significantly led to suppression of 4T1 tumor volumes when compared with the control group treated with vehicle at a dose of 5 mg/kg (Fig. 10B) , suggesting that CD could inhibit tumor growth in vivo.
(A) CD regulates b-catenin levels through modulation of the GSK-3b in BT-549 cells. Cells were treated with CD (0, 5, 10, and 20 lM for 24 h) and then harvested. Total cell lysates were prepared and 40 lg proteins was subjected to SDS-PAGE followed by western blot analysis and chemiluminescence detection. Equal loading of protein was confirmed by stripping the western blot and reprobing it for b-actin. Band intensities were quantified using NIH Image J software. The relative protein levels phosphorylated Akt (p-Akt ser473 ), total Akt (Total-Akt), phosphorylated GSK-3b (p-GSK-3b), b-catenin using their specific antibodies as specified in materials and methods. Each value was calculated on the basis of the data obtained from three independent experiments. Representative bar diagram showing quantitative results for relative levels of (B) p-Akt ser473 /total Akt, (C) p-GSK3b/b and b-catenin proteins for CD treated cells. (E) Cells co-treated with CD and GSK3b inhibitors LiCl (20 mM) for 24 h. Total cell lysates were prepared and 40 lg proteins was subjected to SDS-PAGE followed by western blot analysis and chemiluminescence detection. Equal loading of protein was confirmed by stripping the western blot and reprobing it for b-actin. Band intensities were quantified using NIH Image J software. The relative protein levels of b-catenin using their specific antibodies as specified in materials and methods. Each value was calculated on the basis of the data obtained from three independent experiments. Representative bar diagram showing quantitative results for relative level of (F) b-catenin proteins for treated cells. Values are the means 6 SEM (n 5 3). ***P < 0.001, **P < 0.01, and *P < 0.05 versus control.
FIG 9
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Discussion
Aberrant activation of the Wnt/b-catenin signaling pathway promotes a myriad of cellular activities such as proliferation, migration, invasion and cell cycle disruption, as well as suppresses apoptosis in many human malignancies including TNBC [22, 51] . Inhibitors of Wnt/b-catenin signaling clearly hold great promise for the delay of TNBC tumorigenesis and metastasis. For the past decade, the intense effort to search for Wnt/b-catenin signaling antagonists among natural products has led to the discovery of numerous effective candidates. In the current study, we investigated the potential of CD in the inhibition of EMT in breast cancer cells and elucidated the underlying molecular mechanisms.
Anti-cancer effects of CD have been reported in many types of cancer [25, 26, 54, 55] . The present study demonstrated that CD exhibited antiproliferative effect and apoptosis-against triple-negative MDA-MB-231 and BT-549 cells without harming the normal breast epithelial MCF10A cells. Apoptosis is one of the modes of cell death and induction of apoptosis is the key characteristic of anticancer drugs as it plays an imperative role in the elimination of damaged cells and the maintenance of homeostasis and many of the natural chemopreventive agents exert their effect via induction of apoptosis in cancer cells. Previous studies revealed that CD inhibited the growth of the tumor cell proliferation by inducing apoptosis, results of present study were consistent with previously reported results [25, 26, 55, 56] . Apoptosis is characterized by distinct morphological features such as cell shrinkage, chromatin condensation, plasma membrane blebbing, oligonucleosomal DNA fragmentation, and finally breakdown of the cell into smaller units (apoptotic bodies) [57] [58] [59] . Anticancer agents with different modes of action have been reported to trigger apoptosis in chemosensitive cell.
Our findings showed that CD induced the apoptotic cell death associated with activation and cleavage of caspase-3 in TNBC cells. Next we demonstrated the effect of CD on Bcl-2 family proteins, including the anti-apoptotic (e.g., Bcl-2) and pro-apoptotic proteins (e.g., Bax). The balance between these two groups could profoundly affect cellular response to undergo apoptosis or not [60, 61] . This interaction ablates prosurvival function and activates the Bax which render the cells to undergo apoptosis by permeabilizing the mitochondrial outer membrane. Mitochondria are important organelles which are involved to release of apoptotic signals during an intrinsic pathway for the execution of apoptosis [62] . Dysfunction of mitochondria leads to the dissipation of mitochondrial transmembrane potential and subsequently release of pro-apoptotic proteins, such as cytochrome c, from inner membranes of mitochondria, leading to activation of executioner caspase-3 to induce apoptosis [63] . It is one of the mechanisms of caspase activation in a mainly apoptotic cell death. Fragmentation of cellular DNA at the internucleosomal linker regions has been observed in cells undergoing apoptosis. Because of their characteristic patterns revealed by agarose gel electrophoresis, these nucleosomal DNA ladders are widely used as biochemical markers of apoptosis [64] . Consistently, cleavage of caspase-3 and poly-(ADP-ribose) polymerase (PARP) were enhanced by treatment of CD in TNBC cells.
EMT has been implicated in cancer initiation, invasion, migration, metastasis, and drug resistance [65] . A number of previous studies have shown that regulation of EMT may represent an emerging therapeutic approach to fight against TNBC. EMT depends on a reduction in expression of cell adhesion molecules and loss of tight junctions. E-cadherin can act as an active suppressor of invasion and growth of many epithelial cancers are able to form a continuous barrier to fluids across the epithelium and endothelium [66] . In the present study, our findings demonstrated that CD treatment significantly increased the expression level of E-cadherin in BT-549 cells. In fact, E-cadherin mediates calcium-dependent cell-cell adhesion, which is also suppressed by snail/slug [67] , and our data showed that CD treatment inhibited the expression of slug, which in turn might result in the increased expression of E-cadherin. Furthermore, b-catenin can act as an integral component of a protein complex in adherent junctions, which helps cells maintain epithelial layers, and b-catenin participates in the Wnt signaling pathway as a downstream target [50, 68] . CD treatment decreased the expression of b-catenin in TNBC cells. In the presence of BTZ which is a proteasomal inhibitor (A) Representative images of 4T1 induced tumors after treatment with CD at a dose of 2.5 and 5 mg/kg (B) Growth of the tumors were measured by measuring tumor volumes. Values are the means 6 SEM (n 5 10). ***P < 0.001, **P < 0.01, and *P < 0.05 versus control.
FIG 10
[69] CD induced degradation of b-catenin was inhibited in BT-549 cells. It confirmed that CD inhibits wnt/b-catenin signaling by proteasomal degradation of b-catenin. Another important finding of our study was the downregulation of slug by CD treatment, as slug/snail axis has been proposed to be repressor of E-cadherin in breast carcinomas. Increased expression of Ecadherin is suggestive of reduced EMT, which clearly has implications in tumor invasion and metastasis [70] . In BT-549 cells, we showed that CD modulated the expression of Ecadherin by significantly downregulating the levels of slug and snail protein, supporting the potential use of CD in anti-cancer metastasis therapy of TNBC.
Given the increased E-cadherin expression by CD, we hypothesize that CD modulates the EMT program by targeting Wnt/b-catenin signaling. Concomitantly, CD regulated the expression, cellular distribution, and transcriptional activity of b-catenin. The patterns strongly correlate with the increased protein levels of E-cadherin with a reduced invasive BT-549 cell phenotype. The accumulation of both cytosolic and nuclear b-catenin was reduced. Several Wnt target genes such as cyclin D1, c-Myc, VEGF, and CDK-4 play important roles in tumorigenesis: cyclin D1 and c-Myc regulate cell proliferation and cell cycle progression. Downregulation of these apoptotic genes represent an advantage in controlling metastatic behavior in TNBC [71] . For instance, c-myc is reported to induce a more aggressive phenotype and metastatic features in TNBC. Altogether, our results suggested that the suppression of cyclin D1, c-Myc, VEGF, and CDK-4 by CD may collectively delayed tumorigenesis and metastasis in TNBC cell lines.
The other important component of Wnt pathway investigated in our study was GSK3b. Normally; cytoplasmic pool of bcatenin is maintained by the activity of GSK3b and other components of destruction complex. Wnt signaling facilitates Dvlmediated phosphorylation of GSK3b thereby facilitating the increase of cytoplasmic and nuclear pool of b-catenin [72] [73] [74] . Our results showed that CD attenuated the GSK-3b phosphorylation levels at Ser 9 and down-regulated b-catenin abundance. We further provide evidence suggesting that this activation of GSK-3b is due to inhibition of Akt activity caused by CD. Interestingly, inhibition of GSK-3b activity by LiCl decreased the downregulation of b-catenin protein induced by CD. On CD treatment, the expression of phosphorylated GSK3b was decreased in a concentration-dependent manner and we cogitate that this unphosphorylated GSK3b (active) leads to the degradation of b-catenin through ubiquitin-dependent mechanism. The diagrammatic representation depicting the possible mechanisms involved in CD mediated protection against human triple breast cancer cell invasiveness by downregulation of Wnt/b-catenin signaling cascades and reversal of EMT is illustrated in (Fig. 11) .
Schematic diagram illustrating modulation of Wnt/b-catenin signaling by CD.
FIG 11
In conclusion, to our knowledge this is the first evidence that CD reverses the EMT process with the downregulation of Wnt/b-catenin signaling, as well as invasive and migratory phenotypes. Our explorations of the underlying mechanisms reveal that CD maintains E-cadherin expression through the limitation of b-catenin nuclear localization. Collectively, this study gives insight into the specific pathways that are required for CD mediated EMT inhibition and put forth CD as a rational therapeutic strategy for TNBC treatment.
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